- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Immunomedics wins $7.5 million financing
In a deal that generated $7.5 million in financing, radiopharmaceutical firm Immunomedics last month sold 2.5 million shares of its common stock to Paramount Capital of New York. The transaction gives Paramount Capital a 6% share in the company.Morris
In a deal that generated $7.5 million in financing, radiopharmaceutical firm Immunomedics last month sold 2.5 million shares of its common stock to Paramount Capital of New York. The transaction gives Paramount Capital a 6% share in the company.
Morris Plains, NJ-based Immunomedics plans to use the proceeds of the stock sale to redeem remaining shares of its outstanding preferred stock. In November, the company made an agreement with HFTP Investment to buy 445 of HFTPs preferred shares in the company. The holder of the firms remaining 150 preferred shares, which Immunomedics declined to name, has also agreed to sell those shares to the firm.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI Have an Impact with Fertility-Sparing Treatments for Endometrial and Cervical Cancers?
January 9th 2025In a literature review that includes insights from recently issued guidelines from multiple European medical societies, researchers discuss the role of magnetic resonance imaging (MRI) in facilitating appropriate patient selection for fertility-sparing treatments to address early-stage endometrial and cervical cancer.
